Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | WNT1 | P04628 | 3/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30142384 | 0.85 | DYRK1A (0.51) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142319 | 0.85 | RAB9A (0.48) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142285 | 0.84 | YTHDC1 (0.59) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142246 | 0.83 | WNT1 (0.62) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142245 | 0.83 | WNT1 (0.49) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142244 | 0.83 | WNT1 (0.49) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142289 | 0.82 | DYRK1A (0.41) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142268 | 0.81 | WNT1 (0.64) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142404 | 0.81 | KDM4E (0.43) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 | |
| SCHEMBL30142357 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2KDM4ERAB9ANPC1WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | claimed |
| US-20250000859-A1 | USE OF GCN2 INHIBITORS IN TREATING CANCER | Alesta Therapeutics BV (NL) | 2025-01-02 | — | — | US | disclosed |
| WO-2023025912-A1 | USE OF GCN2 INHIBITORS IN TREATING CANCER | Alesta Therapeutics BV (NL) | 2023-03-02 | — | — | WO | disclosed |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | HIBERCELL, INC. | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250000859-A1 | USE OF GCN2 INHIBITORS IN TREATING CANCER | GCN1, EIF2AK4, UNG | SMN1; SMN2 4143/4885KDM4E 2180/4885RAB9A 3340/4885 |
| US-20220388964-A1 | (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | EIF2AK4, GCN1, GNAI2 | SMN1; SMN2 1591/4885KDM4E 2876/4885RAB9A 1575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.